AUTO-1/22 is under clinical development by Autolus Therapeutics and currently in Phase II for Hairy Cell Leukemia. According to GlobalData, Phase II drugs for Hairy Cell Leukemia have a 17% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AUTO-1/22’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AUTO-1/22 overview
AUTO-1NG is under development for the treatment of relapsed or refractory acute lymphoblastic leukemia, Burkitt lymphoma, acute myelocytic leukemia (AML, acute myeloblastic leukemia), chronic lymphocytic leukemia (CLL), chronic myelocytic leukemia (CML, chronic myeloid leukemia), hairy cell leukemia, Hodgkin lymphoma (B-cell Hodgkin lymphoma) in pediatrics. It is a chimeric antigen receptor (CAR) T cell therapy comprising of CD19 CAR of AUTO-1 and a novel CD22 CAR. The drug candidate acts by targeting CD19 and CD22 expressing cancer cells.
Autolus Therapeutics overview
Autolus Therapeutics (Autolus) is a clinical-stage biopharmaceutical company. It offers programmed T-cell therapies for the treatment of hematological cancers and solid tumors. Autolus pipeline products include Obe-cel, AUTO1/22, AUTO5, AUTO6NG, AUTO7 and AUTO8. The company applies its extensive cell programming capability to develop a pipeline of precise, controlled and highly active products as it is both safe and the most therapeutically effective approach to manufacturing CAR T cells. Autolus is headquartered in London, England, the UK.
For a complete picture of AUTO-1/22’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
